Bremer Trust National Association reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 35.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,156 shares of the biopharmaceutical company’s stock after selling 3,389 shares during the quarter. Bremer Trust National Association’s holdings in Gilead Sciences were worth $435,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in GILD. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. increased its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Penserra Capital Management LLC increased its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Webster Bank N. A. increased its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. Finally, American Beacon Advisors Inc. purchased a new stake in shares of Gilead Sciences in the first quarter valued at approximately $143,000. Institutional investors own 74.05% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Bremer Trust National Association Sells 3,389 Shares of Gilead Sciences, Inc. (GILD)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/16/bremer-trust-national-association-sells-3389-shares-of-gilead-sciences-inc-gild.html.

A number of research firms have recently commented on GILD. Jefferies Group LLC restated a “hold” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 11th. BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price target (up from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Robert W. Baird reiterated an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Thursday, July 13th. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Leerink Swann reiterated a “market perform” rating on shares of Gilead Sciences in a research report on Thursday, June 22nd. Eleven analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $83.79.

Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.09% during midday trading on Friday, hitting $82.36. The stock had a trading volume of 12,401,948 shares. The firm has a 50 day moving average price of $77.16 and a 200 day moving average price of $70.20. The stock has a market cap of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the previous year, the business earned $3.08 EPS. The company’s revenue was down 8.2% on a year-over-year basis. Equities analysts expect that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

In other news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at $3,684,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold 466,819 shares of company stock worth $36,740,240 over the last ninety days. 1.30% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.